Intermediate-Dose Idebenone and Quality of Life in Friedreich Ataxia

Pediatric Neurology

Volumn 42, Issue 5, 2010, Pages 338-342

  Brandsema, John F ^a   Stephens, Derek ^a   Hartley, Jessica ^a   Yoon, Grace ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IDEBENONE; UBIQUINONE;

ADOLESCENT; ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFECT; EMOTION; FEMALE; FRIEDREICH ATAXIA; HUMAN; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PEDIATRIC QUALITY OF LIFE INVENTORY; PERCEPTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SOCIAL ASPECT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; FOLLOW UP; PSYCHOLOGY;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; FEMALE; FOLLOW-UP STUDIES; FRIEDREICH ATAXIA; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; UBIQUINONE;

EID: 77950618866     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2010.01.004     Document Type: Article

References (26)

1. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol 256 Suppl. 1 (2009) 3-8
2. Corben L.A., Georgiou-Karistianis N., Fahey M.C., et al. Towards an understanding of cognitive function in Friedreich ataxia. Brain Res Bull 70 (2006) 197-202
3. Campuzano V., Montermini L., Moltò M.D., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
4. Schulz J.B., Dehmer T., Schöls L., et al. Oxidative stress in patients with Friedreich ataxia. Neurology 55 (2000) 1719-1721
5. Delatycki M.B., Williamson R., and Forrest S.M. Friedreich ataxia: an overview. J Med Genet 37 (2000) 1-8
6. De Michele G., Perrone F., Filla A., et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients. Neurology 47 (1996) 1260-1264
7. Voncken M., Ioannou P., and Delatycki M.B. Friedreich ataxia: update on pathogenesis and possible therapies. Neurogenetics 5 (2004) 1-8
8. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., and Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60 (2003) 1676-1679
9. Di Prospero N.A., Sumner C.J., Penzak S.R., Ravina B., Fischbeck K.H., and Taylor J.P. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 64 (2007) 803-808
10. Meier T., and Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol 256 Suppl. 1 (2009) 25-30
11. La Pean A., Jeffries N., Grow C., Ravina B., and Di Prospero N.A. Predictors of progression in patients with Friedreich ataxia. Mov Disord 23 (2008) 2026-2032
12. Di Prospero N.A., Baker A., Jeffries N., and Fischbeck K.H. Neurolo-gical effects of high-dose idebenone in patients with Friedreich's ataxia: a randomized, placebo-controlled trial. Lancet Neurol 6 (2007) 878-886
13. Tonon C., and Lodi R. Idebenone in Friedreich's ataxia. Expert Opin Pharmacother 9 (2008) 2327-2337
14. Pineda M., Arpa J., Montero R., et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 12 (2008) 470-475
15. Riazi A., Cano S.J., Cooper J.M., Bradley J.L., Schapira A.H., and Hobart J.C. Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes?. Mov Disord 21 (2006) 1396-1403
16. Epstein E., Farmer J.M., Tsou A., et al. Health related quality of life measures in Friedreich ataxia. J Neurol Sci 272 (2008) 123-128
17. Hobart J.C., Cano S.J., Zajicek J.P., and Thompson A.J. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. [Erratum in: Lancet Neurol 2008;7:25]. Lancet Neurol 6 (2007) 1094-1105
18. Storey E., Tuck K., Hester R., Hughes A., and Churchyard A. Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord 19 (2004) 190-192
19. Lynch D.R., Farmer J.M., Tsou A.Y., et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology 66 (2006) 1711-1716
20. Trouillas P., Takayanagi T., Hallett M., et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145 (1997) 205-211
21. Delatycki M. Evaluating the progression of Friedreich ataxia and its treatment. J Neurol 256 Suppl. 1 (2009) 36-41
22. Varni J.W., Burwinkle T.M., Seid M., and Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 3 (2003) 329-341
23. Varni J.W., Limbers C.A., and Burwinkle T.M. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes 5 (2007) 43
24. Fahey M.C., Corben L., Collins V., Churchyard A.J., and Delatycki M.B. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry 78 (2007) 411-413
25. Ribaï P., Pousset F., Tanguy M.L., et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 64 (2007) 558-564
26. Schulz J.B., Di Prospero N.A., and Fischbeck K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol 256 Suppl. 1 (2009) 42-45